Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Clinical evidence

CORE-001

60 evidence topics · 16 sources

Objective
Location and study date
Study dates, enrollment, and sites in the ClinicalTrials.gov record
Study characteristicQuoted record
Study start (actual)“2020-12-08”
Primary completion (actual)“2023-03-07”
Study completion (actual)“2024-05-28”
Enrollment (actual)“35”
Sites“This study has 19 locations”
Enrollment by country in the published final results
Study design
Single-arm, open-label design in the ClinicalTrials.gov record
Design characteristicQuoted record
Phase“Phase 2”
Allocation“N/A”
Interventional model“Single Group Assignment”
Masking“None (Open Label)”
Collaborator“Merck Sharp & Dohme LLC”
Eligibility criteria
Key inclusion criteria in the clinical study protocol

“Be ≥18 years of age (or legal age of majority in the jurisdiction) on day of signing informed consent.” (opens the source at this quote in a new tab)

“Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.” (opens the source at this quote in a new tab)

“Relapsed or persistent CIS (with or without TaHG or T1 disease) within 12 months of the completion (last dose) of adequate BCG treatment for HGUC (e.g., CIS, TaHG, T1, or a combination of these HGUC pathologies).” (opens the source at this quote in a new tab)

“Pathological confirmation of BCG unresponsive CIS within 10 weeks of study enrollment.” (opens the source at this quote in a new tab)

“CIS specimen must be predominantly urothelial (transitional cell) and have less than 50% variant (e.g., sarcomatoid, squamous etc. component) histology.” (opens the source at this quote in a new tab)

“Have all Ta and/or T1 disease resected and all CIS resected or fulgurated, as feasible, prior to study treatment (e.g., prior to Day 1 treatment).” (opens the source at this quote in a new tab)

“At least 5 of 6 doses of an initial induction course (adequate induction) plus at least 2 of 3 doses of maintenance therapy, OR” (opens the source at this quote in a new tab)

“At least 5 of 6 doses of an initial induction course (adequate induction) plus at least 2 of 6 doses of a second induction course.” (opens the source at this quote in a new tab)

“Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy based on Investigator assessment.” (opens the source at this quote in a new tab)

Treatment
Study outcomes
Rationale for using complete response at 12 months as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline characteristics in the published final results
Characteristicn = 35
Age, median“72”
Age, range“57–90”
Sex, male“33 (94.3)”
Sex, female“2 (5.7)”
ECOG 0“25 (71.4)”
ECOG 1“9 (25.7)”
ECOG 2“1 (2.9)”
Race, White“27 (77.1)”
Race, Black/African American“2 (5.7)”
Race, Asian“5 (14.3)”
Race, unknown“1 (2.9)”
Stage, CIS“27 (77.1)”
Stage, CIS + high-grade Ta“4 (11.4)”
Stage, CIS + high-grade T1“4 (11.4)”
Prior BCG courses, 2“18 (51.4)”
Prior BCG courses, 3“8 (22.9)”
Prior BCG courses, 4“2 (5.7)”
Prior BCG courses, 5“4 (11.4)”
Prior BCG courses, ≥6“3 (8.6)”
Prior BCG instillations and persistent or recurrent disease in the interim presentation
CharacteristicQuoted value
Number of prior BCG instillations, median (range)“12 (9 - 30)”
Persistent high-risk NMIBC, n“21”
Persistent high-risk NMIBC, %“60”
Recurrent high-risk NMIBC, n“14”
Recurrent high-risk NMIBC, %“40”
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-related adverse effects by maximum severity
Preferred termGrade 1, n (%)Grade 2, n (%)Grade 3, n (%)Total (N = 35), n (%)
Participants with at least one study drug-related treatment-emergent adverse effect“9 (25.7)”“18 (51.4)”“5 (14.3)”“32 (91.4)”
Bladder spasm“13 (37.1)”“4 (11.4)”“0”“17 (48.6)”
Fatigue“11 (31.4)”“2 (5.7)”“0”“13 (37.1)”
Dysuria“8 (22.9)”“1 (2.9)”“0”“9 (25.7)”
Pollakiuria“8 (22.9)”“1 (2.9)”“0”“9 (25.7)”
Hematuria“5 (14.3)”“1 (2.9)”“0”“6 (17.1)”
Micturition urgency“4 (11.4)”“2 (5.7)”“0”“6 (17.1)”
Diarrhea“4 (11.4)”“0”“1 (2.9)”“5 (14.3)”
Nocturia“3 (8.6)”“1 (2.9)”“0”“4 (11.4)”
Hypothyroidism“1 (2.9)”“3 (8.6)”“0”“4 (11.4)”
Urinary tract infection“3 (8.6)”“1 (2.9)”“0”“4 (11.4)”
Blood alkaline phosphatase increased“0”“0”“1 (2.9)”“1 (2.9)”
Ejection fraction decreased“0”“0”“1 (2.9)”“1 (2.9)”
Neutrophil count decreased“0”“0”“1 (2.9)”“1 (2.9)”
Adrenal insufficiency“0”“0”“1 (2.9)”“1 (2.9)”
Immune-mediated hepatitis“0”“0”“1 (2.9)”“1 (2.9)”
Study limitations
Summary

CORE-001 was a single-arm, open-label phase 2 trial of 35 participants with no control arm, so the contribution of cretostimogene to the combination cannot be separated from that of pembrolizumab within the trial. The protocol tested a 12-month complete response rate of 19% (H0) against 36% (Ha) at a one-sided alpha of 0.10 with approximately 81% power, and required 30 evaluable participants. The 12-month complete response rate was 57.1% (20 of 35; 95% CI 40.7% to 73.5% in the publication and 39.5% to 73.2% in the annual report). The 24-month complete response rate was 51.4% (18 of 35) in the publication and 54% (19 of 35) at the later May 17, 2024 data cutoff reported by the company. Long-term efficacy and survival follow-up stopped under Protocol Amendment 7, so data beyond 24 months were not collected. Thirty of 35 participants (85.7%) were enrolled in the USA and 5 (14.3%) in Korea; 33 (94.3%) were male. Pembrolizumab dosing changed during the trial from 200 mg every 3 weeks to 400 mg every 6 weeks, and the DDM concentration is described as 5% in the protocol synopsis and registry record and as 0.1% in the protocol administration procedure. An author correction removed the abstract statements that attributed immune-related adverse effects exclusively to pembrolizumab, and added that attribution of adverse effects to pembrolizumab was “assessed by the treating physicians”. Long-term follow-up assessments were based on local review.